Background: Radiotherapy is essential in the management of head–neck cancer. During the course of radiotherapy, patients may develop significant anatomical changes. Re-planning with adaptive radiotherapy may ensure adequate dose coverage and sparing of organs at risk. We investigated the consequences of adaptive radiotherapy on head–neck cancer patients treated with volumetric-modulated arc radiation therapy compared to simulated non-adaptive plans: Materials and methods: We included in this retrospective dosimetric analysis 56 patients treated with adaptive radiotherapy. The primary aim of the study was to analyze the dosimetric differences with and without an adaptive approach for targets and organs at risk, particularly the spinal cord, parotid glands, oral cavity and larynx. The original plan (OPLAN) was compared to the adaptive plan (APLAN) and to a simulated non-adaptive dosimetric plan (DPLAN). Results: The non-adaptive DPLAN, when compared to OPLAN, showed an increased dose to all organs at risk. Spinal cord D2 increased from 27.91 (21.06–31.76) Gy to 31.39 (27.66–38.79) Gy (p = 0.00). V15, V30 and V45 of the DPLAN vs. the OPLAN increased by 20.6% (p = 0.00), 14.78% (p = 0.00) and 15.55% (p = 0.00) for right parotid; and 16.25% (p = 0.00), 18.7% (p = 0.00) and 20.19% (p = 0.00) for left parotid. A difference of 36.95% was observed in the oral cavity V40 (p = 0.00). Dose coverage was significantly reduced for both CTV (97.90% vs. 99.96%; p = 0.00) and PTV (94.70% vs. 98.72%; p = 0.00). The APLAN compared to the OPLAN had similar values for all organs at risk. Conclusions: The adaptive strategy with re-planning is able to avoid an increase in dose to organs at risk and better target coverage in head–neck cancer patients, with potential benefits in terms of side effects and disease control.

Background: Hypo-fractionation can be an effective strategy to lower costs and save time, increasing patient access to advanced radiation therapy. To demonstrate this potential in practice within the context of temporal evolution, a twenty-year analysis of a representative radiation therapy facility from 2003 to 2022 was conducted. This analysis utilized comprehensive data to quantitatively evaluate the connections between advanced clinical protocols and technological improvements. The findings provide valuable insights to the management team, helping them ensure the delivery of high-quality treatments in a sustainable manner. Methods: Several parameters related to treatment technique, patient positioning, dose prescription, fractionation, equipment technology content, machine workload and throughput, therapy times and patients access counts were extracted from departmental database and analyzed on a yearly basis by means of linear regression. Results: Patients increased by 121 ± 6 new per year (NPY). Since 2010, the incidence of hypo-fractionation protocols grew thanks to increasing Linac technology. In seven years, both the average number of fractions and daily machine workload decreased by −0.84 ± 0.12 fractions/year and −1.61 ± 0.35 patients/year, respectively. The implementation of advanced dose delivery techniques, image guidance and high dose rate beams for high fraction doses, currently systematically used, has increased the complexity and reduced daily treatment throughput since 2010 from 40 to 32 patients per 8 h work shift (WS8). Thanks to hypo-fractionation, such an efficiency drop did not affect NPY, estimating 693 ± 28 NPY/WS8, regardless of the evaluation time. Each newly installed machine was shown to add 540 NPY, while absorbing 0.78 ± 0.04 WS8. The COVID-19 pandemic brought an overall reduction of 3.7% of patients and a reduction of 0.8 fractions/patient, to mitigate patient crowding in the department. Conclusions: The evolution of therapy protocols towards hypo-fractionation was supported by the use of proper technology. The characteristics of this process were quantified considering time progression and organizational aspects. This strategy optimized resources while enabling broader access to advanced radiation therapy. To truly value the benefit of hypo-fractionation, a reimbursement policy should focus on the patient rather than individual treatment fractionation.

Patient-specific quality assurance (PSQA) procedures ensure the safe delivery of volumetric modulated arc therapy (VMAT) plans. PSQA requires extensive time and resources and may cause treatment delays if replanning is needed due to failures. Recently, our group developed a machine learning (ML) model predicting gamma passing rate (GPR) for VMAT arcs. This study explores automatable replanning strategies for plans identified at risk of failure, aiming to improve deliverability while maintaining dosimetric quality. Between 2022 and 2023, our ML model analyzed 1252 VMAT plans. Ten patients having a predicted GPR (pGPR) <95% were selected. Replanning strategies consisted of limiting monitor units (MUlimit) and employing the aperture shape controller (ASC) tool. Re-optimized plans were compared with the originals in terms of dose volume constraints (DVCs) for the target and organs-at-risk (OARs), and deliverability using the modulation complexity score (MCS), pGPR, and measured GPR (mGPR). Forty-five re-optimizations were performed. Replanning led to an increase in DVCs for OARs and a reduction for the target. Complexity decreased, reflected by the increase in the MCS from 0.17 to 0.21 (MUlimit) and 0.20 (ASC). The deliverability improved, with the pGPR increasing from 93.3% to 94.4% (MUlimit) and 95.1% (ASC), and the mGPR from 99.3% to 99.7% (MUlimit) and 99.8% (ASC). Limiting the MUs or utilizing the ASC reduced the complexity of plans and improved the GPR without compromising the dosimetric quality. These strategies can be used to automate replanning procedures, reduce the workload related to PSQA, and improve patient safety.

Stereotactic radiosurgery (SRS) for multiple brain metastases can be delivered with a single isocenter and non-coplanar arcs, achieving highly conformal dose distributions at the cost of extreme modulation of treatment machine parameters. As a result, SRS plans are at a higher risk of patient-specific quality assurance (PSQA) failure compared to standard treatments. This study aimed to develop a machine-learning (ML) model to predict the PSQA outcome (gamma passing rate, GPR) of SRS plans. Five hundred and ninety-two consecutive patients treated between 2020 and 2024 were selected. GPR analyses were performed using a 3%/1 mm criterion and a 95% action limit for each arc. Fifteen plan complexity metrics were used as input features to predict the GPR of an arc. A stratified and a time-series approach were employed to split the data into training (1555 arcs), validation (389 arcs), and test (486 arcs) sets. The ML model achieved a mean absolute error of 2.6% on the test set, with a 0.83% median residual value (measured/predicted). Lower values of the measured GPR tended to be overestimated. Sensitivity and specificity were 93% and 56%, respectively. ML models for virtual QA of SRS can be integrated into clinical practice, facilitating more efficient PSQA approaches.